Company Filing History:
Years Active: 2018-2019
Title: The Innovative Journey of Inventor Hun-Ho Jo in Cancer Research
Introduction
Hun-Ho Jo is an accomplished inventor based in Busan, South Korea, renowned for his contributions to cancer treatment through innovative drug complexes. With a portfolio of three patents to his name, he is at the forefront of developing targeted therapies that enhance the efficacy of chemotherapy.
Latest Patents
Hun-Ho Jo's latest patents showcase his expertise in creating sophisticated anticancer drug complexes.
1. The **AGTR1 aptamer-anticancer drug complex for cancer cell chemotherapy** is a significant advancement that focuses on selectively targeting AGTR1-positive breast cancer cells. This complex includes a nucleic acid aptamer specifically designed to bind to the AGTR1 receptor, which allows for the precise delivery of anticancer drugs to overexpressed cancer cells, thereby improving treatment outcomes.
2. Another notable innovation is the **HER2 aptamer-anticancer drug complex for cancer cell chemotherapy**. This method involves a two-step process of preparing a nucleic acid aptamer with a specific base sequence for HER2 and forming an aptamer-anticancer drug complex. This invention aims to enhance the selectivity and efficiency of cancer treatment by targeting HER2-positive cells.
Career Highlights
Hun-Ho Jo is affiliated with the Korea University Research and Business Foundation, where he contributes to groundbreaking research in cancer therapies. His dedication to innovation in pharmaceutical development has positioned him as a key figure in the science community, particularly in the realm of targeted chemotherapy.
Collaborations
Throughout his career, Hun-Ho Jo has collaborated with esteemed colleagues such as Jae-Hong Seo and Ji-young Kim. These partnerships have fostered a dynamic research environment that encourages the exchange of ideas and the development of cutting-edge cancer treatment solutions.
Conclusion
Hun-Ho Jo's innovative work in the field of cancer therapy reflects his commitment to improving patient outcomes through targeted treatment strategies. His patents on the AGTR1 and HER2 aptamer-anticancer drug complexes exemplify the potential of precision medicine in oncology. As he continues to push the boundaries of scientific research, his efforts will undoubtedly have a lasting impact on the fight against cancer.